Esperion new data on bempedoic acid in Diverse Populations

 Patients With Obesity Who Took NEXLETOL Were 23% Less Likely to Experience a Major Adverse Cardiovascular Event (MACE-4) Compared to Placebo –

– NEXLETOL Demonstrated Clinical Benefit in Historically Underrepresented Groups: Women and Hispanic/Latinx Patients With and Without Cardiovascular Disease (CVD) –

– CLEAR Outcomes Sets New Standards for Diversity and Inclusion with Enrollment of 48% Women and 17% Hispanic/Latinx Patients –

https://www.globenewswire.com/news-release/2024/04/07/2858842/0/en/Esperion-Presents-Important-New-Data-from-CLEAR-Outcomes-at-ACC-24-Highlighting-Value-of-NEXLETOL-bempedoic-acid-Tablets-in-Diverse-Populations-Including-Women-Hispanics-Latinx-and.html